Patient no. | Sex | Age (y) | Pathology | Grade | Prior treatment | Blood glucose (mg%) | Dexamethasone (mg/d) | Better delineated by delayed imaging? |
---|---|---|---|---|---|---|---|---|
1 | F | 45 | GM | HG | Resect/RT/Gamma Knife*/CHT | 71 | 4–6 | Y |
2 | M | 48 | GM | HG | Resect/RT/125I seeds/Gliadel†/CHT | 81 | NA | Y |
3 | M | 52 | GM | HG | Resect/RT/CHT | 104 | 16 | Y |
4 | F | 68 | GM | HG | Resect/RT | 85 | 6 | Y |
5 | M | 40 | GS | HG | Resect/RT/CHT | 86 | NA | Y |
6 | F | 59 | AOA | HG | None | 109 | NA | Y |
7 | M | 29 | AOA | HG | Resect/RT | 100 | NA | N |
8 | M | 49 | AOA | HG | Resect/RT | 83 | NA | N |
9 | F | 27 | AO | HG | Resect/RT/Gamma Knife/CHT | 94 | NA | Y |
10 | F | 41 | AO | HG | Resect/RT/CHT | 105 | NA | Y |
11 | F | 42 | AO | HG | Resect/RT/CHT | 95 | NA | Y |
12 | F | 41 | Mixed A/O | PLG | Biopsy/RT | 82 | NA | Y |
13 | M | 62 | Astro | PLG | Biopsy/RT | 91 | NA | N |
14 | M | 36 | Astro | PLG | Biopsy/RT | 62 | NA | Y |
15 | M | 41 | Oligo | PLG | Biopsy | 109 | NA | N |
16 | M | 38 | Oligo | PLG | Biopsy/RT | 133 | 12 | Y |
17 | M | 42 | Oligo | SLG | Resect only | 99 | NA | N |
18 | M | 51 | Oligo | SLG | Biopsy/CHT | 108 | NA | N |
19 | M | 75 | Gliomatosis | SLG | None | 113 | NA | N |
GM = glioblastoma multiforme; GS = gliosarcoma; AOA = WHO grade 3 mixed astrocytoma/oligodendroglioma; AO = WHO grade 3 oligodendroglioma; mixed A/O = WHO grade 2 astrocytoma/oligodendroglioma; astro = WHO grade 2 astrocytoma; oligo = WHO grade 2 oligodendroglioma; HG = high grade; PLG = progressive low grade; SLG = stable low grade; resect = resection; RT = radiotherapy; CHT = chemotherapy.
↵* Elekta AB.
↵† Guilford Pharmaceuticals Inc.